Led · Series B · Oct 2025

VitriVax is a Boulder, Colorado–based vaccine formulation technology company focused on its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform. ALTA® is designed to eliminate cold-chain requirements and consolidate multi-dose regimens into single-shot vaccines, thereby easing distribution to remote or resource-limited regions. The company is advancing the platform toward Phase 1-ready GMP manufacturing and first-in-human trials. Recent funding will support scale-up of clinical, regulatory, and commercial operations. VitriVax’s non-dilutive funding includes a $9.9 million Bill & Melinda Gates Foundation grant, a grant from the Coalition for Epidemic Preparedness Initiatives (CEPI), and a multi-year contract from the U.S. Department of Defense. These resources position the company to accelerate development and broaden access to lifesaving immunizations worldwide.

Participated · Series B · Mar 2025

Curevo is a clinical-stage biotechnology company focused on developing vaccines with improved tolerability and accessibility. Its lead product, amezosvatein, is a non-mRNA adjuvanted sub-unit vaccine designed to prevent shingles. The company raised $110M in a Series B to accelerate clinical development. Curevo intends to use the funds to extend its Phase 2 program by an additional 640 participants, including adults over age 70, to finalize dose selection ahead of Phase 3. Leadership includes CEO George Simeon, and the financing is accompanied by additions to the board to support late-stage development planning. The company is based in Seattle, WA. Curevo Vaccine is a Seattle-based, clinical-stage biotech focused on developing safe, highly effective subunit vaccines using an adjuvanted platform. Its lead candidate, CRV-101, is an adjuvanted subunit vaccine being evaluated to prevent shingles in older adults and was designed to use a smaller amount of adjuvant to aim for comparable efficacy with fewer side effects. In Phase 1, CRV-101 showed robust humoral and cellular immunogenicity with no grade 3 injection-site reactions and a 1.3% rate of grade 3 systemic side effects. CRV-101 is in a head-to-head Phase 2b trial versus Shingrix®, in which Curevo enrolled 678 patients in six months; topline data were expected in early 2023. The company is also developing a non-live subunit chickenpox vaccine. Financially, Curevo completed a $26 million Series A1 financing and previously raised $86 million in 2022, which company management says extends its cash runway. Curevo Vaccine is a clinical-stage biotech based in Seattle focused on developing safe, highly effective adjuvanted subunit vaccines via its sub-unit vaccine technology platform. Its lead product, CRV-101, is an adjuvanted sub-unit vaccine under investigation to prevent shingles in older adults and is designed to use less adjuvant to aim for similar efficacy with fewer side effects. The company reported encouraging Phase 1 data showing robust humoral and cellular immunogenicity, no grade 3 injection-site side effects, and a 1.3% rate of grade 3 systemic side effects. Curevo is conducting a 678-patient Phase 2b trial intended to compare CRV-101’s immunogenicity and safety profile relative to Shingrix. The firm is also developing a non-live subunit chickenpox vaccine to address unmet needs for more accessible vaccines. Curevo announced a $60 million Series A to fund clinical development through topline data from the Phase 2b trial.

Participated · Series C · May 2024

Memo Therapeutics is a late-stage biotech company based in Schlieren, Zurich, developing therapeutic antibodies for viral infections and cancer. Its lead program, AntiBKV, is a neutralizing antibody aimed at treating BK virus infection in kidney transplant recipients. The company holds FDA fast track status for AntiBKV and intends to use new funds to accelerate clinical development. Memo plans to expand its Phase II trial with a dose-evaluation extension supported by the financing. Its pipeline includes additional antibody candidates targeting infectious diseases such as cytomegalovirus (CMV) and immuno-oncology programs, including a partnership with Ono Pharmaceutical. The company is led by CEO Erik van den Berg. Memo Therapeutics AG (MTx) is a late-stage biotech based in Schlieren/Zurich, Switzerland, focused on developing best-in-class therapeutic antibodies for viral infections and cancer. Its lead program, AntiBKV, is a highly effective neutralizing antibody designed to treat BK polyomavirus infection in kidney transplant recipients, a condition that can lead to graft dysfunction and organ rejection. MTx plans to complete a multi-center U.S. Phase II study of AntiBKV and is preparing to scale up CMC manufacturing for a Phase III study and potential market entry. The company expects Phase II clinical data in 2024 and is preparing for a potential launch in 2025. Proceeds from its recent financing will also be used to advance additional pipeline candidates targeting infectious diseases such as CMV and immuno-oncology targets, and to support a partnership with Ono Pharmaceutical. Memo Therapeutics develops antibody discovery and immune repertoire analysis technologies that capture whole B-cell repertoires from any donor species and screen them in single-cell format to identify functional monoclonal antibodies. Its platform uses microfluidic single-cell molecular cloning and screening to assess millions of candidate antibodies and generate recombinant clonal cell lines expressing desired mAbs. The company’s pipeline focuses on infectious diseases and immuno‑oncology, with lead programs MTX-005 (a neutralizing antibody targeting BK virus) and COVAB 36 (an inhaled monoclonal antibody for SARS-CoV-2). Memo plans to use the new funding to advance MTX-005 into Phase 2 clinical development, expand its antibody pipeline, and secure new partnering agreements. The company also lists programs in cytomegalovirus (CMV) and Nipah virus, and says the recent funding together with a Swiss Federal COVID-19 grant will enable advancement of MTX-005 and COVAB 36 into clinical development this year. Memo Therapeutics is a private company based in Bio‑Technopark Zurich, Switzerland. Memo Therapeutics uses a droplet microfluidics-based single-cell platform (Dropzylla®) to capture and preserve entire B-cell repertoires and screen millions of candidate antibodies in functional assays. The platform generates recombinant clonal cell lines expressing monoclonal antibodies and is applied across species and indications for proprietary and partnered projects. The company’s pipeline includes programs in infectious diseases and immuno-oncology; its lead COVID-19 program is COVAB 36, a potent, fully-human monoclonal antibody that can be administered via inhalation. Memo received CHF 10.5 million from the Swiss Federal Funding Programme for COVID-19 Medicines to clinically develop COVAB 36, with the programme implemented by the Swiss Federal Office of Public Health and supported by Innosuisse. Memo completed preclinical development and plans to start phase 1 clinical studies with COVAB 36 in Q1 2022, and the project includes rapid development of a combination antibody partner for emerging variants via an ultra-fast update process. The company is a private firm located in Bio‑Technopark Zurich and was ranked in the TOP 100 Swiss Startups list from 2015 to 2017. Memo Therapeutics AG develops antibody discovery and immune repertoire analysis technologies built on microfluidic single-cell molecular cloning and screening. Its platform captures and preserves entire B-cell repertoires and screens them in single-cell format, assessing millions of candidate antibodies directly in functional assays to produce recombinant clonal cell lines expressing monoclonal antibodies with desired functions. The company’s pipeline includes infectious disease and immuno-oncology programs, with lead assets MTX-COVAB for COVID-19 and MTX-005 for BK virus in renal transplant patients. Memo says MTX-COVAB is a fully human, highly potent antibody that neutralizes all major known mutants and that it has agreed a fast-track development plan with regulators, planning to begin clinical studies in 2021. The CHF 14 million Series B financing will primarily fund advancement of MTX-COVAB through Phase II and GMP production, Phase II development of MTX-005, and expansion of additional anti-infectious candidates and partnering activities. The company is located in Bio-Technopark Zurich, Schlieren, Switzerland.

Participated · Series B · Jan 2024

On February 24, 2021, 依生生物制药有限公司 announced completion of a Series B financing of more than $130 million. The round was co‑led by Oceanpine Capital (海松资本) and OrbiMed (奥博资本). Following the transaction, the company's institutional investor base included Oceanpine, OrbiMed, 斯道资本, F‑Prime Capital, 3W Capital, 高瓴资本, Adjuvant Capital, 和玉资本, AIHC, 益普资本, Superstring Capital and 海通国际. 易凯资本 served as the company's exclusive financial adviser on the deal. The financing expanded the company's investor roster and represents a significant recapitalization event at the B‑round stage. No additional product, operational or use‑of‑proceeds details for the company were provided in the articles.

Participated · Equity · Oct 2023

MinervaX is advancing a prophylactic vaccine against Group B Streptococcus (GBS) based on research from Lund University. Its candidate is a protein-only vaccine composed of fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS (the Alpha-like protein family), distinct from traditional capsular polysaccharide (CPS) conjugate approaches. The company has reported Phase II data suggesting superior efficacy compared with other GBS vaccine candidates. MinervaX intends to use the fresh financing to support commencement of a Phase III clinical trial of its maternal vaccine. The company was established in 2010 and is led by CEO Per Fischer. It is headquartered in Copenhagen, Denmark. MinervaX is a Copenhagen-based biotechnology company led by CEO Per Fischer developing a prophylactic vaccine against Group B Streptococcus (GBS) for maternal immunization. Its vaccine approach is based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS (the Alpha-like protein family) and derives from research at Lund University. The company intends to use the new funding to advance late-stage development of its GBS vaccine candidate in preparation for a Phase 3 clinical trial. Financially, MinervaX raised a total of €72M in the announced financing, comprising a €22M equity round and a €50M loan facility. The €22M equity round was led by Trill Impact Ventures and Pureos Bioventures with participation from REPAIR Impact Fund, Sunstone Life Science Ventures, LF Investment, Wellington Partners, Sanofi Ventures, Adjuvant Capital and Industrifonden. Bita Sehat of Trill Impact Ventures and Veronica Gambillara of Pureos Bioventures will join MinervaX's board as part of the transaction. MinervaX is developing GBS-NN, a maternal vaccine based on two surface proteins (Rib and AlphaC) intended to prevent Group B streptococcus infections in newborns and adverse pregnancy outcomes. Early clinical data indicate subsequent doses raise antibody levels above expected protective thresholds, including in participants with low baseline antibodies. The company completed phase 1 studies in 300 healthy females and has begun a phase 2 program, with the first five subjects dosed in South Africa. The new funding will allow MinervaX to complete phase 2 trials and prepare for phase 3, including midstage trials in the U.S. and Europe. Management highlights a large potential market—WHO estimates ~100 million women will require the vaccine globally and a potential commercial market of about $1 billion annually. MinervaX positions its protein-based approach in contrast to capsular polysaccharide (CPS) conjugate vaccines, which have shown poorer performance in individuals with low pre-existing antibody levels. The company frames the vaccine as a way to reduce reliance on intravenous antibiotics, which are costly and can drive antimicrobial resistance. MinervaX is developing a protein-only GBS vaccine for maternal immunization, based on fusions of immunogenic and protective protein domains from selected surface proteins of GBS (the Alpha-like protein family). The company’s vaccine is positioned as likely to have superior characteristics compared with other GBS vaccine candidates that use traditional capsular polysaccharide conjugate technology. MinervaX is advancing therapies to combat antimicrobial resistance (AMR) and is focused on preventing life-threatening infections in newborns by vaccinating pregnant women. The company plans to use recent funds to finalize Phase I development of its protein-only GBS vaccine. MinervaX was established in 2010 and is led by CEO Per Fischer, D.Phil. Its work is based on research from Lund University.